Bordeaux, France / October 11th, 2022 – TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. [Read more…]
Sponsored Content: Press releases may be published as paid or sponsored content. The issuers of these press releases are solely responsible for their content. BioInformant is not responsible for the accuracy or claims made in these announcements and does not endorse the views expressed by their issuers.
Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement
Fully integrated companies streamline access to genetically modified stem cells for clinical development
October 6, 2022, Seattle, Washington – Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technological and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients. [Read more…]
CPD-017 by Kataoka Corporation to Streamline iPSC Processing for the US Market
Los Angeles, California, October 5, 2022 – Kataoka Corporation (Kyoto, Japan) and Kataoka-SS America Corporation (Carson, CA) have developed the CPD-017, a cell processing platform that uses cutting edge laser and AI technology to purify adherent iPSC cultures. [Read more…]
CRISPR Therapeutics Announces FDA RMAT Designation Granted to CTX130™ for Treatment of Cutaneous T-Cell Lymphomas
ZUG, Switzerland and BOSTON, Sept. 28, 2022 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS). [Read more…]
Defence Therapeutics Reports Reprogrammed MSC Vaccine Cures 80% of Animals with Lymphoma Cancer
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia, September 21, 2022 – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence’s novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma. [Read more…]
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 118
- Next Page »